Shoulder Innovations, Inc. (SI)
AI stock analysis · as of May 26, 2026
Loading microstructure…
Shoulder Innovations (SI) is a recently IPO'd (August 2025) pure-play shoulder implant company targeting the ~$1.7B U.S. shoulder arthroplasty market with a differentiated two-tray system optimized for the ambulatory surgery center (ASC) shift, paired with its ProVoyance AI planning software. Revenue grew ~50% to $47.3M in 2025 with ~77% gross margins, but the company burns ~$36M in FCF and posted a $40M net loss. The core investment question is whether SI's ASC-native design and software lock-in can let it take meaningful share from entrenched orthopedic giants (Stryker, Zimmer, DePuy) fast enough to reach profitability before cash and debt capacity run out.
valuationAt ~$311M market cap on $47M revenue, SI trades at ~6.6x trailing sales — fair-to-rich for med-tech but reasonable if 50%+ growth and ~77% gross margins persist; with no positive earnings, P/S and growth durability are the only anchors, and the -10.8x forward P/E underscores the profitability gap.
This analysis is from May 26, 2026. Want the latest on SI, plus the ability to generate fresh research on demand?
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.
Bull case
- · 50% procedure volume growth and reported 65% sales jump (per news) materially outpaces the underlying ~11% market growth, indicating real share gains against larger incumbents
- · Structural ASC tailwind: CMS added total shoulder arthroplasty to ASC-covered procedures in 2024, and SI's two-tray system is purpose-built for this outpatient shift — a defensible product-market fit
- · Software moat building: ProVoyance used in ~100% of 2025 procedures creates surgeon workflow lock-in, with robotics platform in development to extend differentiation
- · Strong gross margins (~77%) consistent with premium orthopedic implants — once scale arrives, operating leverage should be substantial
- · Pipeline catalysts: metal-sensitivity implant 510(k) cleared Jan 2026, plus fracture and revision systems expand the addressable wallet per surgeon
- · Insider conviction: CEO buying shares post-IPO and raised 2026 guidance support management confidence; strong-buy consensus from 4 analysts with $21.25 mean target (~42% upside)
Bear case
- · Cash burn is severe: $36M FCF outflow against only $26.9M cash and $15M debt — company likely needs to raise capital within 12-18 months, risking dilution at depressed prices
- · Net loss widened from $15.6M (2024) to $40.4M (2025), and net margin deteriorated from -49% to -85% despite revenue scaling, suggesting operating leverage is not yet materializing
- · Competitive intensity from Stryker, Zimmer Biomet, DePuy Synthes, and Arthrex — all vastly better capitalized, with established surgeon relationships and bundled portfolios
- · Highly concentrated commercial strategy targeting only ~1,800 of 15,000 shoulder surgeons makes the business vulnerable to losing a handful of key accounts
- · Inventory/implant-set capital intensity is a known cash drain in orthopedics and could worsen if procedure forecasting misses
- · Small float (~20.6M shares), recent IPO, and related-party transactions (Genesis Software license) add governance and liquidity risk
Catalysts
- · Q2 2026 earnings on August 11, 2026 — first key test of whether raised 2026 guidance is tracking
- · Goldman Sachs healthcare conference appearance — potential for institutional sponsorship pickup
- · Commercial ramp of metal-sensitivity implant (510(k) cleared January 2026) and pipeline rollouts (fracture, revision systems)
- · Robotics platform development milestones and any integration announcement with ProVoyance
- · Potential secondary offering or convertible — overhang risk but also clears uncertainty
- · International market entry announcements (currently zero presence in ~$1B ex-U.S. opportunity)
Key risks
- · Capital raise / dilution risk within 12-18 months given $36M annual burn vs $26.9M cash
- · Slower-than-expected ASC migration or pricing pressure from hospital/ASC cost containment
- · Single-source supplier or contract manufacturer disruption
- · Trinity loan covenants or convertible note (matures Sept 2028) refinancing risk if growth decelerates
- · Surgeon concentration — defection of high-volume accounts to competitor platforms
- · Lock-up expiration could create selling pressure given recent IPO
What to watch
- · August 11, 2026 earnings — revenue trajectory and any guidance revision
- · Cash burn rate and any signal of capital raise (watch for S-1/S-3 filings)
- · ASC procedure mix and average revenue per surgeon trends in quarterly disclosures
- · Insider transactions — continued CEO buying vs. lock-up expiration selling
- · Key technical levels: 52-week high $17.94 (breakout) and $10.92 low (support)
- · Competitor commentary from Stryker/Zimmer on shoulder segment share dynamics
Key metrics
Price target rationale
Base case ~$17 applies ~7-8x forward sales on ~$70M 2026 revenue (~45% growth), in line with high-growth med-tech peers. Bull case ~$24 assumes accelerated ASC adoption, sustained 50%+ growth, and software/robotics premium driving 9-10x sales. Bear case ~$9 reflects dilutive capital raise, growth deceleration to ~25-30%, and multiple compression to 4-5x sales as cash concerns dominate.
On Wall Street's view (mixed): The $21.25 consensus target (~42% upside) is plausible if SI sustains 40%+ growth and the ASC thesis plays out, but with only 4 analysts (likely IPO underwriters), cash burn pressure, and inevitable dilution, the street target feels optimistic on timing. A base case closer to fair value with a wide bull/bear band better reflects the binary outcome distribution.
Latest filing (10-K)
Shoulder Innovations is a newly public, fast-growing but unprofitable shoulder implant pure-play that grew procedure volume 50% in 2025 and is betting its differentiated two-tray system and AI planning software will dominate the ASC-driven shift in a $2.7B global market.
Shoulder Innovations, Inc. (NYSE: SI) is a commercial-stage medical technology company exclusively focused on shoulder arthroplasty. It sells advanced implant systems (anatomic and reverse total shoulder arthroplasty) along with an AI-powered preoperative planning tool (ProVoyance) and a proprietary two-tray instrument system. Revenue is generated by selling implant systems to hospitals and ambulatory surgery centers (ASCs), supported by a network of independent distributors and 45 in-house shoulder specialists.
What the news says · bullish
The dominant storyline for SI (Shoulder Innovations) is meaningfully positive: the company reported a 65% sales jump and raised its 2026 outlook, which likely drove the ~20% single-day surge covered by Motley Fool in May 2026. CEO insider buying (lifting stake to 300,018 shares) adds a constructive signal. The one cautionary note comes from Canaccord cutting its price target on Quantum-SI (a different company sharing the ticker) due to weak results, which adds minor noise. Coverage is moderately thin and heavily polluted by unrelated Sports Illustrated and generic market-hours articles, so confidence in this read is limited.
This analysis is from May 26, 2026. Markets move. Get the current read on SI and generate fresh AI research on any ticker.
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.